In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Specialty Pharma, First Horizon's Low Cost Sales Model

Executive Summary

In 2003, after a string of bad luck that had sent its stock down 81%, First Horizon overhauled its management team and began to implement a new low-cost sales strategy. It appears to be working. First quarter 2004 income was $8.2 million, compared to a loss of almost $14 million a year ago. Prescriptions of its key product, calcium channel blocker nisoldipine (Sular), were up 10% in the quarter, and this was evidently enough to convince pharmaceutical company SkyePharma PLC to grant the specialty pharma US marketing rights to an unnamed cardiovascular product.
Advertisement

Topics

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV002359

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel